Abstract
Purpose: To evaluate cytotoxic and antitumor effects of a conventional anticancer drug Doxorubicin (Dox) and photodynamic therapy (PDT) mediated by a promising photosensitizer of second generation meta-tetra (3-hydroxyphenyl)-chlorin (mTHPC) in combination. Methods: Murine hepatoma MH-22A was used for investigation in vitro and in vivo. In vitro, the cells were incubated with 0.15 μg/ml mTHPC for 18 h and exposed to light from LED array (λ= 660±20 nm) at 0.6–2.4 kJ/m2. 0.05–0.2 μg/ml Dox was administered either 24 h prior to or immediately after light exposure (Dox→PDT or PDT + Dox, respectively). The cytotoxicity was tested by staining with crystal violet. The character of the combined effect was assessed by multiple regression analysis. In vivo, the antitumor activity was estimated by monitoring the tumor volume over time, in mice transplanted subcutaneously with MH-22A and treated with Dox and/or PDT. For PDT, mice were exposed to light from diode laser (λ=650±2 nm) at 12 kJ/m2 following 24 h after administration of 0.15 mg/kg mTHPC. A 3 mg/kg Dox was administered either within 15 min prior to mTHPC or within 15 min after light exposure (Dox→PDT or PDT + Dox, respectively). Results: Both in vitro and in vivo, the combination of mTHPC-mediated PDT and Dox was evaluated to be more effective than each treatment alone. In vitro, the difference between cell viability curves after photodynamic treatment as a single modality and after combination of photodynamic treatment with Dox was statistically significant under most of the applied conditions (P≤0.02). In the case of PDT + Dox, the combination had an additive character, and the sequence Dox→PDT caused a sub-additive interaction. In vivo, both regimens of combination were more effective in inhibiting tumor growth than any single treatment (P<0.09). The antitumor activity of PDT + Dox regimen was more prominent than that of Dox→PDT; however, significance of the difference was not high (P=0.08). Conclusions: These results indicate that Dox potentiates therapeutic efficacy of mTHPC-mediated PDT and vice versa, and the degree of potentiation is influenced by the combination schedule: administration of Dox immediately after light exposure is preferable to administration of Dox at 24 h prior to light exposure.
Similar content being viewed by others
References
Baas P, Murrer L, Zoetmulder FA, Stewart FA, Ris HB, Van Zandwijk N, Peterse JL, Rutgers EJ (1997) Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 76:819–826
Bonnett R, White RD, Winfield UJ, Berenbaum MC (1989) Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J 261:277–280
Bonnett R (1999) Photodynamic therapy in historical perspective. Rev Contemp Pharmacother 10:1–17
Boyle RW, Dolphin D (1996) Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol 64:469–485
Brophy PF, Keller SM (1992) Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma. J Surg Res 52:632–634
Canti G, Nicolin A, Cubeddu R, Taroni P, Bandieramonte G, Valentini G (1998) Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors. Cancer Lett 125:39–44
Casas A, Fukuda H, Riley P, Batlle AM (1997) Enhancement of aminolevulinic acid based photodynamic therapy by adriamycin. Cancer Lett 121:105–113
Cowled PA, Mackenzie L, Forbes IJ (1987) Pharmacological modulation of photodynamic therapy with hematoporphyrin derivative and light. Cancer Res 47:971–974
Dilkes MG, Benjamin E, Ovaisi S, Banerjee AS (2003) Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryngol Otol 117:713–717
Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3:380–387
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905
Friedberg JS, Mick R, Stevenson J, Metz J, Zhu T, Buyske J, Sterman DH, Pass HI, Glatstein E, Hahn SM (2003) A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg 75:952–959
Gelshtein VI (1971) Progression of transplanted murine hepatomas. Cytologiya 13:3–13
Gonzalez S, Arnfield MR, Meeker BE, Tulip J, Lakey WH, Chapman JD, McPhee MS (1986) Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole. Cancer Res 46:2858–2862
Herrera-Ornelas L, Petrelli NJ, Mittelman A, Dougherty TJ, Boyle DG (1986) Photodynamic therapy in patients with colorectal cancer. Cancer 57:677–684
Ito M (1984) Microassay for studying anticellular effects of human interferon. J Interferon Res 4:603–609
Kirveliene V, Prasmickaite L, Kadziauskas J, Bonnett R, Djelal BD, Juodka B (1997) Post-exposure processes in Temoporfin photosensitized cells in vitro: reliance on energy metabolism. J Photochem Photobiol B Biol 41:173–180
Kostron H, Fritsch E, Grunert V (1988) Photodynamic therapy of malignant brain tumours: a phase I/II trial. Br J Neurosurg 2:241–248
Ma L, Moan J, Berg K (1994) Evaluation of a new photosensitizer, meso-tetra-hydroxyphenyl-chlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers. Int J Cancer 57:883–888
Mickuviene I, Kirveliene V, Juodka B (2004) Experimental survey of non-clonogenic viability assays for adherent cells in vitro. Toxicol In Vitro 18:639–648
Moan J, Berg K (1991) The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53:549–553
Nahabedian MY, Cohen RA, Contino MF, Terem TM, Wright WH, Berns MW, Wile AG (1988) Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J Natl Cancer Inst 80:739–743
Nathan TR, Whitelaw DE, Chang SC, Lees WR, Ripley PM, Payne H, Jones L, Parkinson MC, Emberton M, Gillams AR, Mundy AR, Bown SG (2002) Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 168:1427–1432
Peterson CM, Shiah JG, Sun Y, Kopeckova P, Minko T, Straight RC, Kopecek J (2003) HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer. Adv Exp Med Biol 519:101–123
Priebe W (ed) (1995) Anthracycline antibiotics. New analogues, methods of delivery, and mechanisms of action. American Chemical Society, Washington DC, 380 p
Ris HB, Altermatt HJ, Nachbur B, Stewart CM, Wang Q, Lim CK, Bonnett R, Althaus U (1996) Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg Med 18:39–45
Rovers JP, Sarnak AE, Molina A, Schuitmaker JJ, Sterenborg HJ, Terpsta OT (1999) Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in rat model. Br J Cancer 81:600–608
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85
Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW (2003) Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res 63:8126–8131
Streckyte G, Didziapetriene J, Grazeliene G, Prasmickiene G, Sukeliene D, Kazlauskaite N, Characiejus D, Griciute L, Rotomskis R (1999) Effects of photodynamic therapy in combination with adriamycin. Cancer Lett 143:1–14
Teiten M-H, Bezdetnaya L, Morliere P, Santus R, Guillemin F (2003) Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells. Br J Cancer 88:146–152
van Geel IP, Oppelaar H, Oussoren YG, Schuitmaker JJ, Stewart FA (1995) Mechanisms for optimising photodynamic therapy: second generation photosensitisers in combination with mitomycin C. Br J Cancer 72:344–350
Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635–692
Weaver JL, Pine PS, Aszalos A, Schoenlein PV, Currier SJ, Padmanabhan R, Gottesman MM (1991) Laser scanning and confocal microscopy of daunorubicin, doxorubicin and rhodamine 123 in multidrug-resistant cells. Exp Cell Res 196:323–329
Zimmermann A, Ritsch-Marte M, Kostron H (2001) mTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol 74:611–616
Zimmermann A, Walt H, Haller U, Baas P, Klein SD (2003) Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient. Cancer Chemother Pharmacol 51:147–154
Acknowledgements
We are indebted to Prof. R. Bonnett (Queen Mary, University of London, UK) for the generous gift of m-THPC and V. Piskarskiene for the excellent care of the cells. This work was partly supported by the European Commission, Program of Centers of Excellence, project CEBIOLA, ICA1-CT-2000–70027, and Lithuanian State Foundation for Science and Studies, Program Light in Biomedicine, P-14/01.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kirveliene, V., Grazeliene, G., Dabkeviciene, D. et al. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo. Cancer Chemother Pharmacol 57, 65–72 (2006). https://doi.org/10.1007/s00280-005-0006-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0006-7